- Haemoctin® becomes the company’s first biological product in the plasma-derived segment, offering a cost-effective alternative for the treatment of hemophilia in the region.
- This partnership reinforces SteinCares’ leadership in expanding access to specialty care therapies for Latin American patients.
San Jose, Costa Rica, October 29, 2024 – SteinCares, a leading specialty healthcare company in Latin America, announces a new distribution agreement with Biotest AG, a multinational company specializing in biological therapies derived from human plasma, for the commercialization and distribution of Haemoctin® throughout selected Latin American countries (Chile, Colombia, Costa Rica, Ecuador, Mexico and Peru). The addition of this plasma-derived factor VIII treatment for hemophilia marks SteinCares’ entry into the plasma-derived therapy segment, expanding its current portfolio of innovative pharmaceuticals, biosimilars, and complex generics.
Hemophilia therapies are essential for the management of this disease, which affects approximately 56,000 people in Latin America. However, according to the World Federation of Hemophilia, only 57% of these patients are diagnosed and about 40% have access to prophylactic treatments. With the introduction of Haemoctin®, SteinCares reaffirms its commitment to increasing access to high-quality and cost-effective specialty care treatments for more patients.
Haemoctin®, indicated for the treatment and prophylaxis of bleeding in patients with hemophilia A, offers an accessible alternative compared to other available treatments. As a plasma-derived product, it ensures high purity and a favorable safety profile.
“The addition of Haemoctin® to our portfolio underscores our commitment to making a meaningful impact on the well-being of hemophilia patients throughout Latin America. By offering a high-quality treatment alternative, we not only improve the economics of healthcare systems through budget balancing and cost effectiveness, but also expand access to safe and effective therapies for patients with rare diseases,” said Sebastian Katz, Chief Strategy Officer at SteinCares.
“We are pleased to partner with SteinCares, their financial and strategic reliability is a key driver to start to penetrate the Latin-American markets with our products, where economic and political challenges have historically presented opportunities for resilient and innovative growth, ” indicates Enrico D’Aiuto, Senior Vice President Commercial Operations at Biotest AG. “With this first agreement, we make Haemoctin® available to hemophilia patients in Latin America. SteinCares’ deep-rooted presence and established operations throughout the region, gives us confidence that this agreement will be a success and will be the first step to its expand our commercial footprint in the LATAM area” highlights Carolin Shah, Vice President responsible at Biotest for the Business Unit Distribution Partners.
About Biotest AG
Biotest is a provider of biological therapeutics derived from human plasma. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialized primarily in the areas of clinical immunology, hematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. Biotest has more than 2,400 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange. Since May 2022, Biotest has been a part of the Grifols Group, based in Barcelona, Spain (www.grifols.com).
About SteinCares
SteinCares is a leader in commercializing and distributing specialty healthcare products in Latin America, including innovative pharmaceuticals, biosimilars and complex generics. With over 40 years of progressive healthcare experience and operations in over 30 countries in Latin America and the Caribbean, SteinCares serves as a bridge between global pharmaceutical companies and the region’s healthcare providers. The company is deeply committed to creating healthcare opportunities that positively impact the lives of patients and their families in Latin America, with a vision of increasing access to innovative and cost-effective healthcare for patients in the region.
For more information, visit http://www.steincares.com/ or follow the company on LinkedIn.
Contact
Victoria Carrillo, Marketing and Corporate Communications Manager
vcarrillo@lbs-cr.com
+54 911-6367-1612